Homburger advises Solenis on the acquisition of Diversey
On March 8, 2023, Solenis announced that it has entered into a definitive merger agreement under which Solenis will acquire Diversey in an all-cash transaction valued at an enterprise value of approximately USD 4.6 bn. Upon completion of the merger, Diversey will become a private company. Headquartered in Wilmington, Delaware, Solenis is a leading manufacturer …
Continue reading “Homburger advises Solenis on the acquisition of Diversey”
Homburger advised a syndicate of banks in connection with the financing of the acquisition of Norline AG
Homburger acted as counsel to Zürcher Kantonalbank as mandated lead arranger, agent, security agent and original lender as well as Credit Suisse (Switzerland) Ltd. and Migros Bank AG as mandated lead arrangers and original lenders in connection with the financing of the acquisition of Norline AG by private equity firm Argos Wityu. Norline AG is …
Homburger advised Nestlé on the issuance of an aggregate of USD 3 bn notes through an institutional (Rule 144A) offering in the United States of America
On March 14, 2023, Nestlé Holdings, Inc. successfully completed its issuance of USD 1 bn 5.250% Notes due 2026, USD 850 m 5.000% Notes due 2028, USD 500 m 4.950% Notes due 2030, and USD 650 m 4.850% Notes due 2033. The Notes are guaranteed by the Nestlé group’s Swiss parent company Nestlé S.A. The …
Homburger advised Credit Suisse on boardroom matters, contingency planning, transactional options, bank regulatory and corporate law aspects in connection with the various measures to support its liquidity situation and the merger of Credit Suisse with UBS
On March 19, 2023, Credit Suisse announced that Credit Suisse and UBS have entered into a merger agreement following the intervention of the Swiss Federal Department of Finance, the Swiss National Bank and the Swiss Financial Market Supervisory Authority FINMA. UBS will be the surviving entity upon closing of the merger transaction. Homburger advised Credit …
Homburger advised Roche Holding Ltd on the issuance of EUR 1.25 bn Bonds
On February 27, 2023, Roche Finance Europe B.V. issued EUR 1.25 bn Bonds guaranteed by Roche Holding Ltd.
Homburger advised Santhera on its financing through a private placement of shares and upsizing of existing financing
On February 28, 2023, Santhera Pharmaceuticals Holding AG (SIX: SANN) announced a private placement of shares and an amendment of its existing financing with funds managed by Highbridge Capital Management, LLC, to provide up to CHF 22.2 m in aggregate, subject to certain milestones and conditions. In addition, Santhera issued 40 m shares in an …
Homburger advises Noema Pharma AG on its USD 112 m Series B financing round
On March 7, 2023, Noema Pharma AG announced that it has successfully closed an oversubscribed Series B financing round, raising CHF 103 m (approx. USD 112 m) from new and existing investors. The round was co-led by the European healthcare focused investment firms Forbion and Jeito Capital. UPMC Enterprises and an additional new investor joined …
Continue reading “Homburger advises Noema Pharma AG on its USD 112 m Series B financing round”
Homburger advised Citigroup Global Markets Inc. in connection with a revolving credit and guaranty agreement
On February 14, 2023 Canacol Energy Ltd. entered into a USD 200 m revolving credit and guaranty agreement with Citigroup Global Markets Inc., Deutsche Bank AG and JPMorgan Chase Bank, N.A. as joint lead arrangers and joint bookrunners.
Homburger advised the controlling shareholder of Reuge on its sale of a majority stake to De Bethune
On February 17, 2023, the controlling shareholder of Reuge SA, the renowned music box producer, successfully completed the sale of a majority stake in the Reuge manufacture to the Swiss luxury watchmaker De Bethune SA.
Homburger advised ADC Therapeutics SA on the Underwritten Offering by a Selling Shareholder
On February 2, 2023, ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company headquartered in Switzerland, announced the pricing of an underwritten offering of 12 m ADCT shares owned by an affiliate of Auven Therapeutics, at a price of USD 5.00 per share. ADCT itself did not sell any shares in the offering.